Article
A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.
Cell reports - 25 Jul 2017
Anderson Grace R, Winter Peter S, Lin Kevin H, Nussbaum Daniel P, Cakir Merve, Stein Elizabeth M, Soderquist Ryan S, Crawford Lorin, Leeds Jim C, Newcomb Rachel, Stepp Priya, Yip Catherine, Wardell Suzanne E, Tingley Jennifer P, Ali Moiez, Xu Mengmeng, Ryan Meagan, McCall Shannon J, McRee Autumn J, Counter Christopher M, Der Channing J, Wood Kris C
Abstract excerpt
Combinatorial inhibition of effector and feedback pathways is a promising treatment strategy for KRAS mutant cancers. However, the particular pathways that should be targeted to optimize therapeutic responses are unclear. Using CRISPR/Cas9, we systematically mapped the pathways whose inhibition cooperates with drugs targeting the KRAS effectors MEK, ERK, and PI3K. By performing 70 screens in models of KRAS mutant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.